Buteyko Method for Asthmatic Children With Mouth Breathing
Not Applicable
Completed
- Conditions
- Mouth BreathingAsthma
- Registration Number
- NCT02724657
- Lead Sponsor
- Universidade Federal do Rio Grande do Norte
- Brief Summary
To assess the effectiveness of the Buteyko method as an adjunct therapy in the treatment of asthmatic children with mouth breathing.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
- Children from 7 up to 12 years old with asthma diagnose
- Regular inhaled corticosteroids with no change in dose in the preceding 4 weeks.
- Children cannot present: other respiratory disease (such as cystic fibrosis, bronchiectasis, and tuberculosis), retinal detachment, hypertensive crisis, congenital heart defect, pulmonary edema, history of lobectomy or lung segmentectomy, respiratory infections 15 days prior to the evaluations.
Exclusion Criteria
- Children that are not able to perform some of the necessary procedures, give up participating in the research and present acute symptoms of respiratory tract during the assessments.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in Sleep disturbance (questionnaire) Baseline, three weeks later and six months after treatment Sleep disturbance will be assessed by the sleep disturbance scale for children (SDSC).
- Secondary Outcome Measures
Name Time Method Change in spirometry (FVC, FEV1, FEV1/FVC, FEF25-75%, PEF) Baseline, three weeks later and six months after treatment Change in ventilometry (minute volume and vital capacity) Baseline, three weeks later and six months after treatment Minute volume and vital capacity (liters)
Number of hospitalizations Through study completion, an average of three weeks and six months after treatment Number of days off-school During the three weeks of treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Buteyko breathing's effects on airway inflammation in asthmatic children with mouth breathing?
How does Buteyko method compare to inhaled corticosteroids in improving FEV1 and reducing exacerbations in pediatric asthma?
Are there specific biomarkers like fractional exhaled nitric oxide (FeNO) that predict response to Buteyko therapy in mouth-breathing asthmatics?
What adverse events are associated with Buteyko breathing retraining in children, and how do they compare to standard asthma therapies?
Can Buteyko method synergize with bronchodilators or leukotriene inhibitors to enhance asthma control in mouth-breathing pediatric patients?
Trial Locations
- Locations (1)
Universidade Federal do Rio Grande do Norte (UFRN)
🇧🇷Natal, Rio Grande do Norte, Brazil
Universidade Federal do Rio Grande do Norte (UFRN)🇧🇷Natal, Rio Grande do Norte, Brazil